Emergence of Tigecycline Resistant Acinetobacter baumannii From an Intensive Care Unit (ICU) in Tehran

AUTHORS

Afsaneh Karmostaj 1 , Shahin Najar Peerayeh 1 , * , Ali Hatef Salmanian 2

1 Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran

2 National Institute of Genetic Engineering and Biotechnology, Tehran, IR Iran

How to Cite: Karmostaj A, Najar Peerayeh S, Hatef Salmanian A. Emergence of Tigecycline Resistant Acinetobacter baumannii From an Intensive Care Unit (ICU) in Tehran, Jundishapur J Microbiol. Online ahead of Print ; 6(3):215-19. doi: 10.5812/jjm.4710.

ARTICLE INFORMATION

Jundishapur Journal of Microbiology: 6 (3); 215-19
Published Online: April 30, 2013
Article Type: Research Article
Received: May 23, 2012
Accepted: August 6, 2012
Crossmark

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Acinetobacter species, specially, Acinetobacter baumannii, is known, as an important opportunistic pathogen, with arnvariety of infections such as pneumonia, bacteraemia, meningitis, urinary tract, skin and soft tissue infections, associated with highrnmortality. High prevalence of multidrug resistance in A. baumannii, limits our therapeutic choices in the treatment of infectionsrncaused by this bacterium.

Objectives: The current study aimed to determine in vitro activity of tigecycline and colistin against clinical isolates of MDR A. baumannii, from patients admitted in ICUs Tehran hospitals.

Material and Methods: This study was conducted from March 2009 to November 2010, on a total of 91 Acinetobacter species isolatedrnfrom clinical specimens in ICUs. All isolates were subjected to PCR to detect blaOXA-51-like gene that is unique to A. baumannii. Thernantimicrobial susceptibility for 13 different antibiotics was tested.

Results: A. baumannii (blaOXA-51-like gene) was detected in 84 (92.30%) isolates.Resistance rates in A. baumannii, were found to bernfor Imipenem 50 (59.52%), Gentamicin 65 (77.38%), Ciprofloxacin 81 (96.42%), Amikacin 44 (52.38%), Cefotaxime 81 (96.42%), Cefepimern69 (82.14%), Ceftazidim 81 (96.42%), Meropenem 74 (88.09%), Trimethoprim - sulfamethoxazole 78 (92.85%), Aztreonam 82 (97.61%),rnColistin and Polymyxin-B 0%. No interpretive criteria have been approved for tigecycline against Acinetobacter spp. so; the results wererninterpreted by the criteria recommended by Jones, and US FDA for Enterobacteriaceae. Resistance rates for tigecycline were 3 (3.57%)rn(Jones criteria) and 19 (22.61%) (FDA criteria).

Conclusions: It is clear that new antimicrobials are needed to treat MDR A. baumannii. Polymyxins and tigecycline are among the fewrnantibiotics available to treat infections with these bacteria but little was known about the antimicrobial activity of these agents. ThernPresent study provided valuable information about the effects of the above mentioned drugs that can be used for health policy. Itrnshould be noted that there is a need for regular surveillance of bacterial resistance to these antimicrobial agents.

Keywords

Acinetobacter baumannii Colistin Tigecycline FDA criteria

© 2013, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: